VisCardia Secures $40 Million Growth Financing to Advance VisONE™ Heart Failure Therapy Toward PMA Approval
PORTLAND, OR, UNITED STATES, December 2, 2025 /EINPresswire.com/ — VisCardia, Inc., a medical device company pioneering a novel cardiac-support therapy for patients with heart failure, today announced it has secured $40 million in growth financing to advance the company’s path toward Premarket Approval (PMA) for its VisONE™ Synchronized Diaphragmatic Stimulation (SDS) Therapy.
The financing will support the execution of the company’s pivotal RECOVER-HF clinical study, and key milestones on the path to PMA. VisCardia expects to achieve the first implant early in 2026. Multiple leading U.S. institutions have already passed site qualification and are nearing patient enrollment, with a strong pipeline of both national and international institutions to follow.
